sf-2052 and isepamicin

sf-2052 has been researched along with isepamicin* in 1 studies

Other Studies

1 other study(ies) available for sf-2052 and isepamicin

Article	Year
[Mechanisms of resistance to dactimicin and isepamicin in clinical strains of gram-negative rods isolated in Czechoslovakia]. Bratislavske lekarske listy, 1992, Volume: 93, Issue:3 Dactamicin is a new member of the pseudo-disaccharide group of antibiotics. It is structurally close to astromicin. Dactimicin is active against a wide variety of bacteria, including resistant strains with aminoglycoside-inactivating enzymes. Isepamicin is a broad-spectrum aminoglycoside, a derivative of gentamicin B. It is also active against many aminoglycoside-resistant strains. In a series of gram-negative bacterial isolates from various Czecho-Slovak regions, in vitro investigation yielded a good activity of dactimicin and isepamicin against amikacin- and gentamicin-resistant strains producing the enzyme AAC/6'/ or a combination of AAC/6'/ + ANT/2"/ enzymes. Dactimicin was not effective against strains producing the enzyme AAC/3/-I, and isepamicin was not effective or only slightly effective against bacterial isolates producing a combination of AAC/6'/ + AAC/3/ enzymes. (Tab. 3, Fig. 2, Ref. 10.). Topics: Aminoglycosides; Anti-Bacterial Agents; Czechoslovakia; Drug Resistance, Microbial; Gentamicins; Gram-Negative Bacteria; Health Facilities	1992

Article

Year

[Mechanisms of resistance to dactimicin and isepamicin in clinical strains of gram-negative rods isolated in Czechoslovakia].

Bratislavske lekarske listy, 1992, Volume: 93, Issue:3

Dactamicin is a new member of the pseudo-disaccharide group of antibiotics. It is structurally close to astromicin. Dactimicin is active against a wide variety of bacteria, including resistant strains with aminoglycoside-inactivating enzymes. Isepamicin is a broad-spectrum aminoglycoside, a derivative of gentamicin B. It is also active against many aminoglycoside-resistant strains. In a series of gram-negative bacterial isolates from various Czecho-Slovak regions, in vitro investigation yielded a good activity of dactimicin and isepamicin against amikacin- and gentamicin-resistant strains producing the enzyme AAC/6'/ or a combination of AAC/6'/ + ANT/2"/ enzymes. Dactimicin was not effective against strains producing the enzyme AAC/3/-I, and isepamicin was not effective or only slightly effective against bacterial isolates producing a combination of AAC/6'/ + AAC/3/ enzymes. (Tab. 3, Fig. 2, Ref. 10.).

Topics: Aminoglycosides; Anti-Bacterial Agents; Czechoslovakia; Drug Resistance, Microbial; Gentamicins; Gram-Negative Bacteria; Health Facilities

1992